Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

  • Technology appraisal guidance
  • TA178
  • Published: 

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal announcement

The Institute have received four appeals from Roche, WyethPharmaceuticals, James Whale Fund for Kidney Cancer and a joint appeal from Rarers Cancer Forum and Macmillan Cancer Support.

The Appeal hearing took place at NICE, MidCity Place 71 High Holborn, London WC1V 6NA - 13 July 2009 at 10:00am.

The institute awaits the decision of the appeal panel

This page was last updated: 30 March 2010